文献

J-GLOBAL ID：202202233032482035   整理番号：22A0623979

同種造血幹細胞移植を受けた小児患者における候補DNA修復遺伝子変異体と急性移植片対宿主疾患の関連研究【JST・京大機械翻訳】

Association study of candidate DNA-repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation

著者 (35件)： Uppugunduri C. R. S. (CANSEARCH Research Platform in Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland) ,  Uppugunduri C. R. S. (Division of Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, Geneva University Hospitals and University of Geneva, Geneva, Switzerland) ,  Huezo-Diaz Curtis P. (CANSEARCH Research Platform in Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland) ,  Huezo-Diaz Curtis P. (Division of Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, Geneva University Hospitals and University of Geneva, Geneva, Switzerland) ,  Nava T. (CANSEARCH Research Platform in Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland) ,  Nava T. (Division of Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, Geneva University Hospitals and University of Geneva, Geneva, Switzerland) ,  Rezgui M. A. (Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada) ,  Mlakar V. (CANSEARCH Research Platform in Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland) ,  Mlakar V. (Division of Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, Geneva University Hospitals and University of Geneva, Geneva, Switzerland) ,  Mlakar S. Jurkovic (CANSEARCH Research Platform in Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland) ,  Mlakar S. Jurkovic (Division of Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, Geneva University Hospitals and University of Geneva, Geneva, Switzerland) ,  Waespe N. (CANSEARCH Research Platform in Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland) ,  Waespe N. (Childhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland) ,  Theoret Y. (Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada) ,  Theoret Y. (Clinical Pharmacology Unit, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada) ,  Gumy-Pause F. (CANSEARCH Research Platform in Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland) ,  Gumy-Pause F. (Division of Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, Geneva University Hospitals and University of Geneva, Geneva, Switzerland) ,  Bernard F. (CANSEARCH Research Platform in Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland) ,  Bernard F. (Division of Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, Geneva University Hospitals and University of Geneva, Geneva, Switzerland) ,  Chalandon Y. (Division of Haematology, Department of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland) ,  Boelens J. J. (Paediatric Blood and Marrow Transplantation Program, University Medical Center Utrecht, Utrecht, The Netherlands) ,  Bredius R. G. M. (Department of Paediatrics, Leiden University Medical Center, Leiden, The Netherlands) ,  Dalle J. H. (Department of Hemato-immunology, Robert-Debre Hospital, Paris-Diderot University, Paris, France) ,  Nath C. (Department of Biochemistry, The Children’s Hospital at Westmead, Westmead, NSW, Australia) ,  Corbacioglu S. (Department of Paediatric Haematology, Oncology and Stem Cell Transplantation, University Hospital of Regensburg, Regensburg, Germany) ,  Peters C. (Department of Pediatrics, St. Anna Children’s Hospital, Medical University of Vienna, Vienna, Austria) ,  Bader P. (Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital, Goethe University Frankfurt, Frankfurt, Germany) ,  Shaw P. (The Cancer Centre for Children, The Children’s Hospital at Westmead, Westmead, NSW, Australia) ,  Bittencourt H. (Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada) ,  Bittencourt H. (Department of Paediatrics, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada) ,  Krajinovic M. (Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada) ,  Krajinovic M. (Clinical Pharmacology Unit, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada) ,  Krajinovic M. (Department of Paediatrics, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada) ,  Ansari M. (CANSEARCH Research Platform in Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland) ,  Ansari M. (Division of Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, Geneva University Hospitals and University of Geneva, Geneva, Switzerland)
資料名： Pharmacogenomics Journal  (Pharmacogenomics Journal)
巻： 22  号： 1  ページ： 9-18  発行年： 2022年 
JST資料番号： W1383A  ISSN： 1470-269X  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： ドイツ (DEU)  言語： 英語 (EN)

抄録/ポイント： 急性移植片対宿主病(aGvHD)グレード2~4は,同種造血幹細胞移植(allo-HSCT)を受けている小児患者の15~60%で生じる。allo-HSCT前に投与した処方による正常組織への側副損傷は,aGvHDに対する最初のトリガーとして機能する。DNA修復機構は,この初期損傷を軽減するのに重要な役割を果たし,従って,対応するDNA修復蛋白質コード遺伝子における変異体を,それらの量や機能に影響することにより,役割を果たす可能性がある。60人の小児患者におけるaGvHDグレード2~4とのそれらの会合のために,17のDNA修復遺伝子内の51の変異体を調査した。aGvHD2~4の累積発生率は,探索コホートで12%(n=7)であった。MGMT rs10764881(G>A)とEXO rs9350(c.2270C>T)変異体は,aGvHD2~4[Odds比=14.8(rs10764881GG群で40から0イベント)と11.5(95%CI:2.3~191.8),それぞれ,多重試験補正p≦0.001]と関連していた。22%(n=40)のaGvHD2~4の発生率を有する拡張コホート(n=182)における評価において,MGMT rs10764881(G>A)のみが,他の臨床危険因子の存在下で有意(調整HR=2.05[95%CI:1.06~3.94];p=0.03)を維持した。より高いMGMT発現は,rs10764881のGGキャリアで見られ,リンパ芽球細胞におけるブスルファンのより高いIC_50と関連していた。MGMT rs10764881キャリア状態は,allo-HSCTを受けている小児患者におけるaGvHD発生を予測することができた。Copyright The Author(s) 2021 Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： *遺伝子 ,  タンパク質 ,  多重化 ,  *DNA修復 ,  人間 ,  母集団 ,  *移植片対宿主病 ,  危険因子 ,  *造血幹細胞移植 ,  脂肪族アルコール ,  スルホン酸エステル ,  ジオール
準シソーラス用語： O(6)-メチルグアニン-DNAメチルトランスフェラーゼ ,  リンパ芽球 ,  *同種造血幹細胞移植 ,  *DNA修復遺伝子 ,  *患児 , 【Automatic Indexing@JST】

分類 (2件)： 遺伝子の構造と化学  (EC02020U) ,  向精神薬の臨床への応用  (GW03110J)

物質索引 (1件)： ブスルファン

タイトルに関連する用語 (6件)： 同種造血幹細胞移植 ,  小児患者 ,  DNA修復遺伝子 ,  変異体 ,  移植片対宿主疾患 ,  研究